Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley

Valeant Pharma (NYSE: VRX) August and September call option implied volatility of 62 compares to its 52-week range of 33 to 173 into Morgan Stanley’s upgrade to Overweight and raising its price target to $42 from $33.

You May Also Be Interested In

• Levi (LEVI) call put ratio 1 call to 1.2 puts into quarter results
• Replimune (REPL) call put ratio 1 call to 1.3 puts with a focus on August options
• Camden Property Trust (CPT) 4500 contracts of July 125 calls trade